Dr Lal PathLabs delivered robust financial results for the quarter ended June 2026, with consolidated net profit rising 27% year-on-year to ₹170 crore. According to latest regulatory filings, the company had posted a profit of ₹132.4 crore in the corresponding quarter of the previous financial year. On a sequential basis, profit demonstrated strong momentum with the latest figures showing continued growth trajectory. The earnings growth reflects steady demand for diagnostic testing services and improved operational efficiency during the quarter.
The company's revenue from operations showed impressive growth, increasing 19.1% year-on-year to ₹798 crore in the June quarter from ₹669.8 crore a year earlier. As reported by Business Standard, compared with the March 2026 quarter, revenue rose 13.5% from ₹702.7 crore. EBITDA grew 28.7% to ₹247 crore, with margin expanding to 31.0% from 28.7% a year ago, representing a 230 basis points improvement. Profit before tax stood at ₹229 crore in Q1 FY27, up 26.3% YoY. The robust revenue growth was supported by improved demand for diagnostic testing services and the company's ability to maintain operational efficiency.
According to Nomura, revenue, EBITDA and PAT came in 4.5%/12.9%/13.3% ahead of estimates driven primarily by higher-than-expected realizations. The brokerage noted that "the beat was driven primarily by higher-than-expected realizations," aided by **(i) price hikes in the CGHS and ECHS schemes (2-3% impact), (ii) a favorable test mix (higher specialized testing), and (iii) a favorable geographic mix (higher contribution from markets with better realization)." Sample volume grew 10.7% year-on-year, while realization per test rose 7.6% y-y - the highest quarterly growth recorded in the past five years. Patient volume increased 8% year-on-year, with realisation per patient up 10% y-y. Management expects "the benefit from the CGHS and ECHS price hikes should continue over the next 2-3 quarters."
Operationally, the company served 8.2 million patients, up 8.2% YoY, while samples processed increased 10.7% YoY to 25.9 million. As reported by Business Standard, material consumed increased 17.8% YoY to ₹152 crore, employee benefit expenses rose 7.3% YoY to ₹133 crore, fees paid to collection centres increased 20.8% YoY to ₹116 crore, and other expenses rose 16.3% YoY to ₹150 crore. SwasthFit contributed 27% of revenue during the quarter, unchanged from a year ago, growing 20% y-y in line with company-level growth. The company maintained its extensive network with 312 clinical laboratories, 7,727 Patient Service Centers, and 13,935 Pick-up Points as of March 2026.
Following the results announcement, shares of Dr Lal PathLabs surged as much as 7.7% on Monday, July 27, reaching a 52-week high after brokerage firm Nomura raised its target price. The stock is now trading 5.6% higher at ₹1,858.5, having made an intraday high of ₹1,894.9. The healthcare service provider's stock has extended its year-to-date advance to 23%, outperforming the benchmark index that has lost 10% in the period. However, ICICI Securities has downgraded the stock to 'Hold' from 'Buy' while raising its target price to ₹1,690 from ₹1,460. The brokerage believes that while the company has reported strong growth for the last two quarters, "sustainability of the run-rate in Q2 FY27 could indicate a trend change." Emkay Global increased FY27/FY28 revenue estimates by 2%/3% respectively, maintaining a 'BUY' rating with a revised target price of ₹2,000. JM Financial valued the stock at 48x Jun'28 EPS, yielding a target price of ₹2,195 while retaining a 'BUY' call. According to Bloomberg analyst recommendations, 25 of the 31 analysts covering the stock have a 'Buy' rating, with the consensus price target at ₹1,907.14, implying a modest upside of about 2%.
Management has upgraded its FY27 revenue growth guidance to mid-teens from early-teens, supported by healthy patient volume growth, better test mix, CGHS and ECHS price revisions, and continued traction across tier-II and tier-III markets. According to CNBC TV18, the management expects the company to trade at the upper end of its pre-COVID valuation range of 40-45 times one-year forward earnings, citing improving growth prospects and sustained margin expansion. The company is investing beyond network expansion with a target of 12-15 lab additions and 3-4 radiology centres during FY27, focusing on high-end tests, radiology, and international-market opportunities. Swasthfit contributed 27% of sales in Q1FY27, broadly stable vs Q1FY26, growing 20% y-y in line with company-level growth. The company recently acquired an 80% stake in Sunshine Healthcare in Ghana for ₹37.7 crore to strengthen its presence in West Africa. The management remains constructive on the structural growth outlook for the industry and indicated the potential to revise its FY27 growth guidance upwards after H1.
Cash and cash equivalents stood at ₹1,693 crore as of June 30, 2026, providing strong financial flexibility for future growth initiatives. The company's board approved strategic acquisitions including the acquisition of a 100% stake in Sunshine Healthcare Limited (SHL), Ghana for up to GHS 45.6 million (₹38 crore) in three tranches, with closing expected by August 31, 2026. Additionally, the board approved subscribing to a 30% stake in Neuome Technologies Private Limited for up to ₹3.5 crore. As of July 27, 2026, Dr Lal PathLabs has a total market capitalisation of ₹31,222.53 crore, with shares trading at ₹1,858 apiece on the National Stock Exchange. The company's board also approved the declaration of an interim dividend of ₹5 per equity share for FY27, with July 30, 2026 set as the record date.
